[Zhenwu Decoction delays ventricular hypertrophy in rats with uremic cardiomyopathy]

Jun Lai1, Yingzhi Wu1, Liwei Hang1

  • 1Department of Cardiology, Heart Center, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.

Insights

Zhenwu Decoction effectively reduces indoxyl sulfate levels and inhibits ventricular hypertrophy in rats with uremic cardiomyopathy, delaying adverse cardiac remodeling. This study highlights its therapeutic potential for kidney disease-related heart conditions.

Area of Science:

  • Cardiovascular Research
  • Nephrology
  • Traditional Chinese Medicine

Background:

  • Uremic cardiomyopathy is a significant complication of chronic kidney disease.
  • Elevated indoxyl sulfate (IS) levels contribute to cardiac hypertrophy and dysfunction in uremia.
  • Ventricular hypertrophy is a key factor in the progression of uremic cardiomyopathy.

Purpose of the Study:

  • To evaluate the inhibitory effects of Zhenwu Decoction on ventricular hypertrophy in a rat model of uremic cardiomyopathy.
  • To elucidate the underlying mechanisms by which Zhenwu Decoction exerts its cardioprotective effects.

Main Methods:

  • In vitro: Rat cardiomyocytes were treated with IS to assess protein synthesis and expression.
  • In vivo: A rat model of uremic cardiomyopathy was established via 5/6 nephrectomy.
  • Treatment groups received varying doses of Zhenwu Decoction; biochemical and histological analyses were performed.

Main Results:

  • IS exposure increased protein synthesis and BNP, p-ERK1/2, and p-p38 expression in cardiomyocytes.
  • Uremic rats exhibited elevated serum creatinine, BUN, 24-h urine protein, IS, and cardiac mass indexes.
  • Zhenwu Decoction treatment significantly reduced IS levels and attenuated ventricular hypertrophy, downregulating myocardial BNP, p-ERK1/2, p-38, and p-JNK expression.

Conclusions:

  • Zhenwu Decoction effectively lowers plasma IS levels in rats with uremic cardiomyopathy.
  • The treatment inhibits ventricular hypertrophy, suggesting a role in delaying ventricular remodeling.
  • These findings support Zhenwu Decoction as a potential therapeutic agent for uremic cardiomyopathy.
Abstract

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
557
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
483
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
526
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
439
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
599
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
354